Synthesis and evaluation of bombesin derivatives on the basis of pan-bombesin peptides labeled with Indium-111, Lutetium-177, and Yttrium-90 for targeting bombesin receptor-expressing tumors

Cancer Research

Volumn 64, Issue 18, 2004, Pages 6707-6715

  Zhang, Hanwen ^a   Chen, Jianhua ^a   Waldherr, Christian ^a   Hinni, Karin ^a   Waser, Beatrice ^b   Reubi, Jean Claude ^b   Maecke, Helmut R ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b UNIVERSITY OF BERN   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE N,N',N''N''' TETRAACETIC ACID GAMMA AMINOBUTYRIC ACID [DEXTRO TYROSYL BETA ALANYLTHIENOYLNORLEUCINE]BOMBESIN; AMINOACYLHISTIDINE DIPEPTIDASE; BETA ALANINE; BOMBESIN DERIVATIVE; BOMBESIN RECEPTOR; CARNOSINE; CELL RECEPTOR; DIETHYLENETRIAMINEPENTAACETIC ACID GAMMA AMINOBUTYRIC ACID [DEXTRO TYROSYL BETA ALANYLTHIENOYLNORLEUCINE]BOMBESIN; EDETIC ACID; ENZYME; GASTRIN RELEASING PEPTIDE; GASTRIN RELEASING PEPTIDE RECEPTOR; HISTIDINE; INDIUM 111; LUTETIUM; LUTETIUM 177; PEPTIDE DERIVATIVE; RADIOLIGAND; RECEPTOR SUBTYPE; UNCLASSIFIED DRUG; YTTRIUM 90;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; CANCER RADIOTHERAPY; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG METABOLISM; DRUG RECEPTOR BINDING; DRUG SCREENING; DRUG SPECIFICITY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; DRUG TISSUE LEVEL; DRUG UPTAKE; EARLY DIAGNOSIS; ENZYME MECHANISM; HUMAN; HUMAN CELL; HUMAN TISSUE; INTERNALIZATION; ISOTOPE LABELING; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; TISSUE DISTRIBUTION;

ANIMALS; BOMBESIN; DRUG STABILITY; HUMANS; INDIUM RADIOISOTOPES; ISOTOPE LABELING; LUTETIUM; MALE; PANCREATIC NEOPLASMS; PROSTATIC NEOPLASMS; RADIOISOTOPES; RADIOPHARMACEUTICALS; RATS; RECEPTORS, BOMBESIN; TISSUE DISTRIBUTION; YTTRIUM RADIOISOTOPES;

EID: 4644360336     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-03-3845     Document Type: Article

References (52)

1. Allen TM. Ligand-targeted therapeutics in anticancer therapy. Nat Rev Cancer 2002;2:750-63.
2. Maison W, Frangioni JV. Improved Chemical Strategies for the Targeted Therapy of Cancer. Angew Chem Int Ed Engl 2003;42:4726-8.
3. Reubi JC. Peptide receptors as molecular targets for cancer diagnosis and therapy. Endocr Rev 2003;24:389-427.
4. Reubi JC. Neuropeptide receptors in health and disease: the molecular basis for in vivo imaging. J Nucl Med 1995;36:1825-35.
5. Behr TM, Behe M, Becker W. Diagnostic applications of radiolabeled peptides in nuclear endocrinology. Q J Nucl Med 1999;43:268-80.
6. Breeman WA, de Jong M, Kwekkeboom DJ, et al. Somatostatin receptor-mediated imaging and therapy: basic science, current knowledge, limitations and future perspectives. Eur J Nucl Med 2001;28:1421-9.
7. Heppeler A, Froidevaux S, Eberle AN, Maecke HR. Receptor targeting for tumor localisation and therapy with radiopeptides. Curr Med Chem 2000;7:971-94.
8. 99mTc-Labeled Small Peptides as Diagnostic Radiopharmaceuticals. Chem Rev 1999;99:2235-68.
9. 99mTc-labelled peptide-based radiopharmaceuticals: an overview. Nucl Med Commun 1999;20:1093-112.
10. Hoffman TJ, Quinn TP, Volkert WA. Radiometallated receptor-avid peptide conjugates for specific in vivo targeting of cancer cells. Nucl Med Biol 2001;28:527-39.
11. Markwalder R, Reubi JC. Gastrin-releasing peptide receptors in the human prostate: relation to neoplastic transformation. Cancer Res 1999;59:1152-9.
12. Sun B, Halmos G, Schally AV, Wang X, Martinez M. Presence of receptors for bombesin/gastrin-releasing peptide and mRNA for three receptor subtypes in human prostate cancers. Prostate 2000;42:295-303.
13. Gugger M, Reubi JC. Gastrin-releasing peptide receptors in non-neoplastic and neoplastic human breast. Am J Pathol 1999;155:2067-76.
14. Halmos G, Wittliff JL, Schally AV. Characterization of bombesin/gastrin-releasing peptide receptors in human breast cancer and their relationship to steroid receptor expression. Cancer Res 1995;55:280-7.
15. Toi-Scott M, Jones CL, Kane MA. Clinical correlates of bombesin-like peptide receptor subtype expression in human lung cancer cells. Lung Cancer 1996;15:341-54.
16. McDonald TJ, Jornvall H, Tatemoto K, Mutt V. Identification and characterization of variant forms of the gastrin-releasing peptide (GRP). FEBS Lett 1983;156:349-56.
17. Minamino N, Kangawa K, Matsuo H. Neuromedin B: a bombesin like peptide identified in porcine spinal cord. Biochem Biophys Res Commun 1983;114:542-8.
18. Von Schrenck T, Heinz-Erian P, Moran T, Mantey SA, Gardner J, Jensen R. Neuromedin B receptor in esophagus: evidence for subtypes of bombesin receptors. Am J Physiol 1989;256:G747-58.
19. Spindel ER, Giladi E, Brehm P, Goodman RH, Segerson TP. Cloning and functional characterization of a complementary DNA encoding the murine fibroblast bombesin/ gastrin-releasing peptide receptor. Mol Endocrinol 1990;4:1956-63.
20. Fathi Z, Corjay MH, Shapira H, et al. BRS-3: a novel bombesin receptor subtype selectively expressed in testis and lung carcinoma cells. J Biol Chem 1993;268:5979-84.
21. 13] bombesin distinct from the receptor for gastrin-releasing peptide: identification of a fourth bombesin receptor subtype (BB4). Proc Natl Acad Sci USA 1995;92:6205-9.
22. 14] bombesin(6-14). Clin Cancer Res 2002;8:1139-46.
23. Schally AV, Nagy A. Cancer chemotherapy based on targeting of cytotoxic peptide conjugates to their receptors on tumors. Eur J Endocrinol 1999;141:1-14.
24. Nagy A, Armatis P, Cai RZ, Szepeshazi K, Halmos G, Schally AV. Design, synthesis, and in vitro evaluation of cytotoxic analogs of bombesin-like peptides containing doxorubicin or its intensely potent derivative, 2- pyrrolinodoxorubicin. Proc Natl Acad Sci USA 1997;94:652-6.
25. Szereday Z, Schally AV, Nagy A, et al. Effective treatment of experimental U-87MG human glioblastoma in nude mice with a targeted cytotoxic bombesin analogue, AN-215. Br J Cancer 2002;86:1322-7.
26. Hu F, Cutler CS, Hoffman T, Sieckman G, Volkert WA, Jurisson SS. Pm-149 DOTA bombesin analogs for potential radiotherapy in vivo comparison with Sm-153 and Lu-177 labeled DO3A-amide-betaAla-BBN(7-14)NH(2). Nucl Med Biol 2002;29:423-30.
27. 4]bombesin, a new radioligand for bombesin-receptor scintigraphy. Int J Cancer 1999;83:657-63.
28. 99mTc-labeling and in vivo studies of a bombesin analogue with a novel water-soluble dithiadiphosphine- based bifunctional chelating agent. Bioconjug Chem 1999;10:254-60.
29. Baidoo KE, Lin KS, Zhan Y, Finley P, Scheffel U, Wagner HN Jr. Design, synthesis, and initial evaluation of high-affinity technetium bombesin analogues. Bioconjug Chem 1998;9:218-25.
30. 99mTc- bombesin detects prostate cancer and invasion of pelvic lymph nodes. Eur J Nucl Med Mol Imaging 2003;30:1378-82.
31. 99mTc-RP527, a gastrin-releasing peptide (GRP) agonist for the visualization of GRP receptor-expressing malignancies. J Nucl Med 2001;42:1722-7.
32. 188Re of peptide conjugates containing a dithia-bisphosphine chelating agent. Bioconjug Chem 2001;12:354-63.
33. Van de Wiele C, Dumont F, Vanden Broecke R, et al. Technetium-99m RP527, a GRP analogue for visualisation of GRP receptor-expressing malignancies: a feasibility study. Eur J Nucl Med 2000;27:1694-9.
34. 99mTc]Demobesin 1, a novel potent bombesin analogue for GRP receptor-targeted tumour imaging. Eur J Nucl Med Mol Imaging 2003;30:247-58.
35. 99mTc(I)- postlabeled high affinity bombesin analogue as a potential tumor imaging agent. Bioconjug Chem 2002;13:599-604.
36. 3. Cancer Res 2003;63:4082-8.
37. 111In-labeled DTPA- or DOTA-bombesin analogs for receptor-targeted scintigraphy and radionuclide therapy. J Nucl Med 2002;43:1650-6.
38. Broccardo M, Falconieri Erspamer G, Melchiorri P, Negri L, de Castiglione R. Relative potency of bombesin-like peptides. Br J Pharmacol 1975;55:221-7.
39. Girard F, Bachelard H, St-Pierre S, Rioux F. The contractile effect of bombesin, gastrin releasing peptide and various fragments in the rat stomach strip. Eur Pharmacol 1984;102:489-97.
40. Mantey SA, Weber HC, Sainz E, et al. Discovery of a high affinity radioligand for the human orphan receptor, bombesin receptor subtype 3, which demonstrates that it has a unique pharmacology compared with other mammalian bombesin receptors. J Biol Chem 1997;272:26062-71.
41. Pradhan TK, Katsuno T, Taylor JE, et al. Identification of a unique ligand which has high affinity for all four bombesin receptor subtypes. Eur Pharmacol 1998;343:275-87.
42. Heppeler A, Froidevaux S, Maecke HR, et al. Radiometal-labelled macrocyclic chelator-derivatised somatostatin analogue with superb tumor-targeting properties and potential for receptor-mediated internal radiotherapy. Chem Eur J 1999;5:1974-81.
43. Wild D, Schmitt JS, Ginj M, et al. DOTA-NOC, a high-affinity ligand of somatostatin receptor subtypes 2, 3 and 5 for labelling with various radiometals. Eur J Nucl Med Mol Imaging 2003;30:1338-47.
44. Atherton E, Sheppard R. Fluorenylmethoxycarbonyl-polyamide solid phase peptide synthesis. General principles and development. Oxford: Oxford Information Press; 1989.
45. Fleischmann A, Laderach U, Friess H, Buechler MW, Reubi JC. Bombesin receptors in distinct tissue compartments of human pancreatic diseases. Lab Invest 2000;80:1807-17.
46. 111In] for SPECT, PET, and targeted therapeutic applications of somatostatin receptor (hsst2) expressing tumors. Bioconjug Chem 2002;13:530-41.
47. 111In-labeled DOTA-biomolecule conjugates. Bioconjug Chem 2002;13:902-13.
48. Maecke HR, Scherer G, Heppeler A, Hennig M. Is In-111 an ideal surrogate for Y-90? If not, why? Eur J Nucl Med 2001;28:967.
49. Teufel M, Saudek V, Ledig JP, et al. Sequence identification and characterization of human carnosinase and a closely related non-specific dipeptidase. J Biol Chem 2003;278:6521-31.
50. Singh P, Draviam E, Guo YS, Kurosky A. Molecular characterization of bombesin receptors on rat pancreatic acinar AR42J cells. Am J Physiol 1990;258:G803-9.
51. Hoffmann T, Simpson S, Smith C, et al. Accumulation and retention of Tc-99m-RP527 by GRP receptor expressing tumors in scid mice. J Nucl Med 1999;40:104P.
52. 64Cu-labeled bombesin analogue. Bioconjug Chem 2003;14:756-63.